Trusted medical expertise in seconds.

Access 1,000+ clinical and preclinical articles. Find answers fast with the high-powered search feature and clinical tools.

Try free for 5 days
Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer.

Autoimmune hepatitis

Last updated: March 26, 2021

Summarytoggle arrow icon

Autoimmune hepatitis (AIH) is a rare form of chronic hepatitis that predominantly affects women. Although the etiology is unclear, it is commonly associated with other autoimmune conditions (e.g., type 1 diabetes mellitus, celiac disease). Clinical presentation varies and patients may be asymptomatic or even show signs of acute liver failure. Diagnosis is established based on the detection of autoantibodies (especially anti-smooth muscle antibodies) and the histologic findings of liver biopsy. Treatment consists of immunosuppressive medications such as prednisone and azathioprine. The prognosis is favorable if patients are treated appropriately; without treatment, cirrhosis may develop.

  • Prevalence: 0.1–2/100,000 white adults in the US, even less so in other ethniticities [1]
  • Bimodal distribution: 10–20 years and 40–60 years [2]
  • Sex: > (∼ 4:1) [3]

Epidemiological data refers to the US, unless otherwise specified.

References:[4]

AIH has an insidious onset in most patients and its presentation varies widely, ranging from asymptomatic disease to severe symptoms or even acute liver failure.

Diagnosis is established based on positive autoantibodies (e.g., anti-smooth muscle antibodies) and histological findings suggestive of autoimmune hepatitis!

References:[4][5]

The differential diagnoses listed here are not exhaustive.

  • 10-year survival rate with treatment: ∼ 90%
    • Lifelong therapy is usually required.
    • Increased risk of developing hepatocellular carcinoma (HCC); therefore, follow-ups are recommended
  • Increased risk of liver cirrhosis if left untreated
  1. Muri Boberg K. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis. 2002; 6 (3): p.635-647. doi: 10.1016/s1089-3261(02)00021-1 . | Open in Read by QxMD
  2. Baven-Pronk MAMC, Biewenga M, van Silfhout JJ, et al. Role of age in presentation, response to therapy and outcome of autoimmune hepatitis.. Clinical and translational gastroenterology. 2018; 9 (6): p.165. doi: 10.1038/s41424-018-0028-1 . | Open in Read by QxMD
  3. Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis.. Am J Gastroenterol. 2002; 97 (8): p.2051-7. doi: 10.1111/j.1572-0241.2002.05921.x . | Open in Read by QxMD
  4. Hardtke-wolenski M, Fischer K, Noyan F, et al. Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4+ T cells. Hepatology. 2013; 58 (2): p.718-28. doi: 10.1002/hep.26380 . | Open in Read by QxMD
  5. Diagnosis and Management of Autoimmune Hepatitis. http://www.aasld.org/sites/default/files/guideline_documents/autoimmunehepatitis2010.pdf. Updated: February 1, 2010. Accessed: December 27, 2016.
  6. Herold G. Internal Medicine. Herold G ; 2014